河北医药
河北醫藥
하북의약
HEBEI MEDICAL JOURNAL
2014年
3期
333-335
,共3页
刘素芬%董正洪%魏娟%冯娜%林琳%吴秀颀%张彦芳%裴艳涛%李兵顺%叶丽红%杨莉
劉素芬%董正洪%魏娟%馮娜%林琳%吳秀頎%張彥芳%裴豔濤%李兵順%葉麗紅%楊莉
류소분%동정홍%위연%풍나%림림%오수기%장언방%배염도%리병순%협려홍%양리
慢性乙型肝炎%替比夫定%阿德福韦酯
慢性乙型肝炎%替比伕定%阿德福韋酯
만성을형간염%체비부정%아덕복위지
chronic hepatitis B%telbivudine%adefovir dipivoxil
目的：探讨替比夫定联合阿德福韦酯对HBeAg阳性慢性乙型肝炎患者的疗效。方法将76例慢性乙型肝炎患者分为干扰素组和替比夫定组，干扰素组应用聚乙二醇干扰素α-2a联合阿德福韦酯，替比夫定组给予替比夫定联合阿德福韦酯，治疗48周，观察血清谷氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）的含量和正常化率及血清HBsAg、HBeAg和乙肝病毒（HBV） DNA的含量及HBeAg阴转率和血清转换率及HBV DNA低于检测下限值率变化。结果2组治疗后24周和48周ALT和AST的含量及血清HBsAg、 HBeAg和HBV DNA的含量均明显降低（ P ＜0．01），而替比夫定组治疗后降低量更显著；ALT和AST正常化率，HBeAg阴转率和血清转换率及HBV DNA低于检测下限值率显著增加（ P ＜0．01），而替比夫定组治疗后的增加量更显著。结论替比夫定联合阿德福韦酯的治疗效果比干扰素联合阿德福韦酯的治疗更加显著。
目的：探討替比伕定聯閤阿德福韋酯對HBeAg暘性慢性乙型肝炎患者的療效。方法將76例慢性乙型肝炎患者分為榦擾素組和替比伕定組，榦擾素組應用聚乙二醇榦擾素α-2a聯閤阿德福韋酯，替比伕定組給予替比伕定聯閤阿德福韋酯，治療48週，觀察血清穀氨痠氨基轉移酶（ALT）和天鼕氨痠氨基轉移酶（AST）的含量和正常化率及血清HBsAg、HBeAg和乙肝病毒（HBV） DNA的含量及HBeAg陰轉率和血清轉換率及HBV DNA低于檢測下限值率變化。結果2組治療後24週和48週ALT和AST的含量及血清HBsAg、 HBeAg和HBV DNA的含量均明顯降低（ P ＜0．01），而替比伕定組治療後降低量更顯著；ALT和AST正常化率，HBeAg陰轉率和血清轉換率及HBV DNA低于檢測下限值率顯著增加（ P ＜0．01），而替比伕定組治療後的增加量更顯著。結論替比伕定聯閤阿德福韋酯的治療效果比榦擾素聯閤阿德福韋酯的治療更加顯著。
목적：탐토체비부정연합아덕복위지대HBeAg양성만성을형간염환자적료효。방법장76례만성을형간염환자분위간우소조화체비부정조，간우소조응용취을이순간우소α-2a연합아덕복위지，체비부정조급여체비부정연합아덕복위지，치료48주，관찰혈청곡안산안기전이매（ALT）화천동안산안기전이매（AST）적함량화정상화솔급혈청HBsAg、HBeAg화을간병독（HBV） DNA적함량급HBeAg음전솔화혈청전환솔급HBV DNA저우검측하한치솔변화。결과2조치료후24주화48주ALT화AST적함량급혈청HBsAg、 HBeAg화HBV DNA적함량균명현강저（ P ＜0．01），이체비부정조치료후강저량경현저；ALT화AST정상화솔，HBeAg음전솔화혈청전환솔급HBV DNA저우검측하한치솔현저증가（ P ＜0．01），이체비부정조치료후적증가량경현저。결론체비부정연합아덕복위지적치료효과비간우소연합아덕복위지적치료경가현저。
Objective To investigate therapeutic effect of telbivudine plus adefovir dipivoxil on HBeAg positive chronic hepatitis B.Methods Seventy-six patients with chronic hepatitis B were divided into pegylated interferon group (pegylated interferon α-2a) and telbivudine group.The patients in pegylated interferon group were treated by pegylated inter -feron plus adefovir dipivoxil ,however,the patients in telbivudine group were treated by telbivudine plus adefovir dipivoxil ,with a treatment course of48 weeks for both groups.The levels of alanine aminotransferase (ALT),aspartate aminotransferase (AST) and the levels of HbsAg,HBeAg and HBV DNA in serum were detected before and after treatment in both groups .ALT and AST normalization rate,HBeAg negative conversion rate and seroconversion rate and rate of undetectable HBV DNA were measured too.Results After 24-week and 48-week treatment,the levels of ALT,AST and the levels of HbsAg,HBeAg and HBV DNA were significantly decreased in both groups ( P <0.01),moreover,the decrease degree in telbivudine group was more obvious than that in pegylated interferon group .ALT and AST normalization rate,HBeAg negative conversion rate and seroconversion rate and the rate of undetectable HBV DNA were significantly increased in both groups after 24-week and 48-week treatment ( P <0.01),moreover,the increase degree in telbivudine group was more obvious than that in pegylated interferon group.Conclusion The therapeutic effect of telbivudine plus adefovir dipivoxil is superior to that of pegylated interferon α-2a plus adefovir dipivoxil in the treatment of chronic hepatitis B .
